Frontiers reaches 6.4 on Journal Impact Factors

This article is part of the Research Topic

Cardio-Oncology: From Bench to Bedside

Mini Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Cardiovasc. Med. | doi: 10.3389/fcvm.2018.00014

Pregnancy and Cardiomyopathy after Anthracyclines in Childhood

  • 1University of Texas MD Anderson Cancer Center, United States

With advances in cancer therapy, there has been a remarkable increase in survival in children diagnosed with malignancies. Many of these children are treated with anthracyclines which are well known to cause cardiotoxicity. As more childhood cancer survivors reach childbearing age, many will choose to become pregnant. At this time, the factors associated with development of cardiomyopathy after anthracycline treatment are not clearly identified. It is possible that cardiac stress could predispose to cardiac deterioration in a patient with reduced functional reserve from prior anthracycline exposure. Pregnancy is one form of cardiovascular stress. The cardiac outcomes of pregnancy in childhood cancer survivors must be considered. In view of limited data, guidelines for pregnancy planning, management, and monitoring after cardiotoxic cancer therapy have not been established. This review summarizes the limited data available on the topic of pregnancy after anthracyclines in childhood.
Keyword: cardiotoxicity, pregnancy, anthracyclines, childhood, survivor

Keywords: cardiotoxicity, Pregnancy, Anthracyclines, childhood, Survivor

Received: 19 Oct 2017; Accepted: 12 Feb 2018.

Edited by:

Burak Pamukcu, Acibadem Kozyatagi Hospital, Turkey

Reviewed by:

Jürgen Bernhagen, Ludwig-Maximilians-Universität München, Germany
Cécile OURY, University of Liège, Belgium  

Copyright: © 2018 Thompson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Kara A. Thompson, University of Texas MD Anderson Cancer Center, Houston, United States,